More about

Autoimmune Liver Disease

News
August 08, 2020
2 min read
Save

‘Steroids and high-dose steroids’ marks new treatment mantra for autoimmune hepatitis

‘Steroids and high-dose steroids’ marks new treatment mantra for autoimmune hepatitis

Aggressive steroid regimens – with doses as high as 60 mg per day – have become the “new mantra” for treating patients with autoimmune hepatitis, according to a presenter at the 2020 Rheumatology Nurses Society Annual Conference.

News
January 16, 2020
2 min read
Save

‘Number to treat’ with UDCA may improve survival rates in PBC

While the absolute clinical efficacy of ursodeoxycholic acid for primary biliary cholangitis varied by baseline prognostic characteristics, study results showed generally high rates of liver transplant-free survival and overall survival.

News
November 07, 2019
1 min read
Save

Seladelpar for PBC moves to phase 3 following positive safety results

Seladelpar for PBC moves to phase 3 following positive safety results

CymaBay Therapeutics achieved its targeted patient enrollment for the EHANCE trial, a phase 3 study of seladelpar for primary biliary cholangitis, and that the company is on track to complete full enrollment by the end of November.

News
October 30, 2019
2 min read
Save

Autoimmune liver disease requires lifelong monitoring as presentation may change

Autoimmune liver disease requires lifelong monitoring as presentation may change

SAN ANTONIO — At this year’s National Liver Congress, Gideon M. Hirschfield, MD, presented real-life cases of patients with primary sclerosing cholangitis along with an overview of how autoimmune liver disease may change over time from initial presentation.

News
October 24, 2019
2 min read
Save

National Liver Conference to cover ‘tsunami’ of new data on liver disease

SAN ANTONIO — The National Liver Congress will convene October 25th, providing a broad scientific program and exhibit of products and services important for all practitioners involved in the care of patients with liver disease.

News
August 26, 2019
3 min read
Save

Pipeline update: 7 reports on autoimmune liver disease therapies

Autoimmune liver diseases include primary biliary cholangitis, primary sclerosing cholangitis, and pediatric diseases such as biliary atresia and progressive familial intrahepatic cholestasis. Researchers continue to investigate and develop potential treatments for both the diseases and their debilitating complications.

News
August 22, 2019
1 min read
Save

Denosumab increases bone mineral density in patients with PBC

Long-term treatment with denosumab increased bone mineral density without any adverse effects in patients with autoimmune liver disease, specifically primary biliary cholangitis, according to the results of a pilot study.

News
August 19, 2019
1 min read
Save

First patient enrolled in proof-of-concept trial for PSC treatment

Immunic announced the first patient enrolled in a proof-of-concept clinical trial of IMU-838 for the treatment of primary sclerosing cholangitis, according to a press release.

News
March 13, 2024
2 min read
Save

A new era for PBC treatment: Expert insights on existing, emerging therapies

A new era for PBC treatment: Expert insights on existing, emerging therapies

Primary biliary cholangitis poses a significant challenge in hepatology, necessitating effective treatment strategies to improve patient outcomes and quality of life.